Navigation Links
Pinnacle Biologics Announces Contract With Chiltern
Date:6/23/2008

ROCKVILLE, Md., June 24 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an agreement with Chiltern International, Inc. for the activities of pharmacovigilence/safety reporting and medical information services for Western Europe.

James R. Miller, President & CEO of Pinnacle Biologics stated, "The completion of the Chiltern agreement represents a significant step in the process of offering a full range of services and solutions to the pharmaceutical/biotechnology companies that we currently represent or will partner with in the future. We are proud to be associated with Chiltern."

"Chiltern is extremely excited about expanding our service portfolio to meet the Pinnacle Biologics unique Pharmocovigilence, Safety and Medical Information requirements and help accelerate the commercialization of pharmaceutical products that are promoted and distributed by Pinnacle," noted Glenn Kerkhof, Chief Executive Officer of Chiltern

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at http://www.pinnaclebiologics.com

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern employs more than 1,200 people with 23 offices across the United States, Europe, Latin America and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further information is available at http://www.chiltern.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1(240)372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
2. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
3. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
6. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
7. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
10. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
11. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental ... wide range of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) ... NDD research and testing. , However, designing a custom panel for disease ...
(Date:7/17/2017)... ... July 17, 2017 , ... Co-Diagnostics, Inc. (NASDAQ: ... intends both to manufacture and sell reagents used for diagnostic tests, has completed ... Headquartered in Sandy, Utah, Co-Diagnostics’ intellectual property and technologies are protected by five ...
(Date:7/16/2017)... N.J. (PRWEB) , ... July 16, 2017 , ... ... laboratory equipment and analytical instruments announced the launch of its new line of ... introduced five rocking and waving shaker models (both analog and digital) for laboratory ...
(Date:7/15/2017)... ... July 15, 2017 , ... Cuvette manufacturer FireflySci has been making ... the people at FFS have learned that their biggest asset was their amazing customer ... to launch new products to meet the changing needs of scientists at a rapid ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):